Alphanate in Immune Tolerance Induction Therapy
A Multicenter Phase 2 Open-Label, Single-Arm, Prospective, Interventional Study of Plasma-Derived Factor VIII/VWF (Alphanate®) in Immune Tolerance Induction Therapy in Subjects With Congenital Hemophilia A
Sponsor: Grifols Biologicals, LLC
Terminated
Terminated due to limited enrollment (non-safety related decision)
Other terminated trials from Grifols Biologicals, LLC
More terminations from Grifols Biologicals, LLC
A PHASE2 clinical study on Hemophilia A, Congenital, this trial is terminated or withdrawn. The trial is conducted by Grifols Biologicals, LLC and has accumulated 17 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
17 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Mar 2021 — Dec 2021 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
▶ Show 12 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
Apr 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Dec 2018 — Apr 2020 [monthly]
Recruiting PHASE2
-
Aug 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Mar 2018 — Apr 2018 [monthly]
Recruiting PHASE2
-
Jan 2018 — Mar 2018 [monthly]
Recruiting PHASE2
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE2
-
Oct 2017 — Dec 2017 [monthly]
Recruiting PHASE2
-
Jul 2017 — Oct 2017 [monthly]
Recruiting PHASE2
-
May 2017 — Jul 2017 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Grifols Biologicals, LLC
- Grifols Therapeutics LLC
For direct contact, visit the study record on ClinicalTrials.gov .